Navigation Links
Switzerland Posts Biotech Gains in 2009
Date:5/26/2010

NEW YORK, May 26 /PRNewswire/ -- Despite a less than favorable global economic environment the Swiss biotechnology industry performed rather well in 2009, reports Mario Brossi, North American senior advisor for Switzerland Trade and Investment Promotion.  According to the Swiss Biotech Report 2010 employment in the sector grew 6% to 19,071 while turnover reached CHF 9.3 billion*, a 7% increase over the prior year.

"The report notes that while the financing environment was challenging, Swiss companies were able to raise CHF 370 million in new capital, led by NovImmune's CHF 60 million in venture capital," Mr. Brossi said.  "BioMedInvest II raised CHF 100 million in new capital and Index Ventures EUR 350 million for early stage investment."

In other activity mondoBiotech floated its shares on the SWX Swiss Exchange, Evolva became public through a reverse merger with Arpida, and ESBATech in a transaction worth up to CHF 600 million was acquired by eye care leader Alcon.

"A measure of a country's ranking in a particular field is the number of patents filed per million of population," Mr. Brossi said.  "The World Patent Index reports that for Switzerland the number of biotech patents registered under this criterion is about 250.  This compares favorably with the U.S. (70), Japan (65), Germany (45), and Great Britain (40).  Much of the country's success in biotech is due to strong Federal support, its network of excellent research institutions and research-oriented industrial players."

According to the Swiss Biotech Report 2010 as of 2009 there were 327 biotech firms in the country, of which 65 are classified as suppliers to the industry.

Switzerland at BIO 2010

At the recently concluded BIO 2010 International Convention in Chicago, Swiss biotech was represented by 18 companies in the Swiss Pavilion and 9 pavilion partners including cantonal and regional economic development agencies, Swiss biotech clusters, the SIX Swiss Exchange, and the country's innovation promotion agency CTI.  Swiss presentations during the technical sessions covered monoclonal antibodies and white (industrial) biotechnology.  The Swiss Delegation was the 10th largest country delegation at BIO.

Further information at www.swissbiotechreport.ch

*1 Swiss Franc (CHF) = ~U.S. $0.86


'/>"/>
SOURCE Switzerland Trade and Investment Promotion
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
2. Accumetrics, Inc. Announces European Distribution Channels for France, Austria, Switzerland, Netherlands, Belgium and Luxembourg
3. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
4. 16th International Process Development Conference to be Held June 14-17, 2009 in Arosa, Switzerland
5. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
6. Pharmaxis Aridol Approved for Sale in Switzerland
7. 220 Companies Place Switzerland First in Biotech Density Per Capita
8. First CyberKnife System Sold in Switzerland
9. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
10. Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007
11. OpenQ Posts a 200% Revenue Growth in the First Half of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)...  VWR Corporation (NASDAQ: VWR), the leading global independent provider ... today reported its financial results for the fourth quarter and ... 4Q16 record quarterly net sales of $1.13 ... basis. 4Q16 EMEA-APAC segment net ... the Americas net sales increased 2.5%, or down 0.9% on ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 ... dollars, except per share data, unaudited)Three Months Ended December ... BioMarin Revenue $     ... 22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... Feb. 23, 2017  MIODx announced today that ... key immunotherapy technologies from the University of California, ... method to monitor a patient for response to ... CTLA-4.  The second license extends the technology with ... likely to have an immune-related adverse event (IRAE) ...
Breaking Biology Technology:
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... , Feb. 7, 2017 The ... largely by the confluence of organizations, desires to ... for knowledge-based systems (password and challenge questions), biometrics ... and government systems. The market is driven by ... demarcation between consumer and enterprise uses cases, with ...
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
Breaking Biology News(10 mins):